The largest database of trusted experimental protocols
> Chemicals & Drugs > Receptor > Binding Sites

Binding Sites

Binding Sites are specialized regions on molecules that interact with other molecules, enabling critical biological processes.
These sites act as docking points, facilitating the binding of ligands, enzymes, and other biomolecules.
Understanding binding site structure and function is essential for drug discovery, protein engineering, and unraveling complex cellular pathways.
Leveraging the power of AI-driven research optimization, tools like PubCompare.ai can help scientists locate relevant protocols, preprints, and patents, while seamlessly comparing the best products and methodologies for binding site analysis.
Expore the possibilities of AI-assisted binding site research and unlock the mysteries of these essential molecular interaction points.

Most cited protocols related to «Binding Sites»

While reading variants from input file, ANNOVAR scans the gene annotation database stored at local disk, and identifies intronic variants, exonic variants, intergenic variants, 5′/3′-UTR variants, splicing site variants and upstream/downstream variants (less than a threshold away from a transcript, by default 1 kb). For intergenic variants, the closest two genes and the distances to them are reported. For exonic variants, ANNOVAR scans annotated mRNA sequences to identify and report amino acid changes, as well as stop-gain or stop-loss mutations. ANNOVAR can also perform region-based annotations on many types of annotation tracks, such as the most conserved elements and the predicted transcription factor binding sites. These annotations must be downloaded by ANNOVAR, before they can be utilized. Finally, ANNOVAR can filter specific variants such as SNPs with >1% frequency in the 1000 Genomes Project, or non-synonymous SNPs with SIFT scores >0.05.
To automate the procedure of reducing large amounts of variants into a small subset of functionally important variants, a script (auto_annovar.pl) is provided in the ANNOVAR package. By default, auto_annovar.pl performs a multi-step procedure by executing ANNOVAR multiple times, each time with several different command line parameters, and generates a final output file containing the most likely causal variants and their corresponding candidate genes. For recessive diseases, this list can be further trimmed down to include genes with multiple variants that are predicted to be functionally important.
Publication 2010
5' Untranslated Regions Amino Acids Binding Sites Exons Gene Annotation Genes Genetic Diversity Genome Introns Mutation Radionuclide Imaging RNA, Messenger Single Nucleotide Polymorphism Transcription Factor
Unassembled sequence reads from both SSU rRNA gene PCR amplicons (pyrotags) and metagenome sequencing were preprocessed (quality control and alignment) by the bioinformatics pipeline of the SILVA project (20 (link)). Briefly, reads shorter than 200 nt or with more than 2% of ambiguities or more than 2% of homopolymers were removed. Remaining reads from amplicons and metagenomes were aligned against the SSU rDNA seed of the SILVA database release 108 (www.arb-silva.de/documentation/background/release-108/) (20 (link)) using SINA (26 (link)). Unaligned reads were not considered in downstream analysis to eliminate non 16S rDNA sequences.
Remaining PCR amplicons were separated based on the presence of aligned nucleotides at E. coli positions of the respective primer binding sites instead of searching for the primer sequences itself. This strategy is robust against sequencing errors within the primer signatures or incomplete primer signatures. This separation strategy works because the amplicon size of one primer pair is significant longer, with overhangs on both 3′ and 5′ site, compared with the amplicon of the second primer pair. With this approach the need for barcoding during combined sequencing of 16S pyrotags derived from different PCR reactions on the same PTP lane was avoided. FASTA files for each primer pair of the separated samples are available online at www.arb-silva.de/download/archive/primer_evaluation.
Reads of the filtered and separated 16S pyrotag datasets as well as metagenomes were dereplicated, clustered and classified on a sample by sample basis. Dereplication (identification of identical reads ignoring overhangs) was done with cd-hit-est of the cd-hit package 3.1.2 (www.bioinformatics.org/cd-hit) using an identity criterion of 1.00 and a wordsize of 8. Remaining sequences were clustered again with cd-hit-est using an identity criterion of 0.98 (wordsize 8). The longest read of each cluster was used as a reference for taxonomic classification, which was done using a local BLAST search against the SILVA SSURef 108 NR dataset (www.arb-silva.de/projects/ssu-ref-nr/) using blast-2.2.22+ (http://blast.ncbi.nlm.nih.gov/Blast.cgi) with default settings. The full SILVA taxonomic path of the best BLAST hit was assigned to the reads if the value for (percentage of sequence identity + percentage of alignment coverage)/2 was at least 93. In the final step, the taxonomic path of each cluster reference read was mapped to the additional reads within the corresponding cluster plus the corresponding replicates (as identified in the previous analysis step) to finally obtain (semi-) quantitative information (number of individual reads representing a taxonomic path). Raw output data are available in the Supplementary Material in Supplementary Tables S48–S50.
Publication 2012
Binding Sites DNA, Ribosomal Escherichia coli FCER2 protein, human Metagenome Nucleotides Oligonucleotide Primers Ribosomal RNA Genes Sequence Alignment SULT1E1 protein, human
We used the Ensembl Variant Effect Predictor (VEP, Ensembl Gene annotation v68)16 (link) to obtain gene model annotation for single nucleotide and indel variants. For single nucleotide variants within coding sequence, we also obtained SIFT7 (link) and PolyPhen-26 (link) scores from VEP. We combined output lines describing MotifFeatures with the other annotation lines, reformatted it to a pure tabular format and reduced the different Consequence output values to 17 levels and implemented a four-level hierarchy in case of overlapping annotations (see Supplementary Note). To the 6 VEP input derived columns (chromosome, start, reference allele, alternative allele, variant type: SNV/INS/DEL, length) and 26 actual VEP output derived columns, we added 56 columns providing diverse annotations (e.g. mapability scores and segmental duplication annotation as distributed by UCSC51 (link),52 (link); PhastCons and phyloP conservation scores53 (link) for three multi-species alignments9 (link) excluding the human reference sequence in score calculation; GERP++ single-nucleotides scores, element scores and p-values54 (link), also defined from alignments with the human reference excluded; background selection score40 (link),55 (link); expression value, H3K27 acetylation, H3K4 methylation, H3K4 trimethylation, nucleosome occupancy and open chromatin tracks provided for ENCODE cell lines in the UCSC super tracks52 (link); genomic segment type assignment from Segway56 (link); predicted transcription factor binding sites and motifs11 (link); overlapping ENCODE ChIP-seq transcription factors11 (link), 1000 Genome variant14 (link) and Exome Sequencing Project57 (link) variant status and frequencies, Grantham scores20 (link) associated with a reported amino acid substitution). The Supplementary Note provides a full description and Supplementary Table 1 lists all columns of the obtained annotation matrix.
Publication 2014
Acetylation Alleles Amino Acid Substitution Binding Sites Cell Lines Chromatin Chromatin Immunoprecipitation Sequencing Chromosomes Gene Annotation Genome Homo sapiens INDEL Mutation Methylation Nucleosomes Nucleotides Open Reading Frames Segmental Duplications, Genomic Transcription, Genetic Transcription Factor
TBA [19] (link) alignments of the human genome (hg18) to 43 other vertebrate species were obtained from the UCSC genome browser [20] (link), [21] (link) together with a phylogenetic tree with the generally accepted topology (Fig S1) and neutral branch lengths estimated from 4-fold degenerate sites. Both the tree and alignments were projected to the 34 mammalian species. The alignment was compressed to remove gaps in the human sequence, and GERP++ scores were computed for every position with at least 3 ungapped species present, or approximately 88.9% of the 3.08 billion positions on the 22 autosomes and X/Y chromosomes. We used the HKY85 [13] (link) model of evolution with the transition/transversion ratio set to 2.0 and nucleotide frequencies estimated from the multiple alignment.
To limit memory requirements and allow parallelization of the constrained element computation, each chromosome was broken up into regions of approximately 2 megabases, with long segments where no RS score was computed chosen as boundaries. These boundary segments contain no information usable by GERP++ and because the algorithm never annotates constrained elements spanning them, excluding such segments did not sacrifice any predictive ability. These boundary regions made up approximately 6.8% of the human genome, including a 30.2 megabase region that made up more than half of chromosome Y. Constrained element predictions were generated using default parameters and a 5% false positive cutoff measured in terms of number of predictions; the estimated nucleotide-level false positive rate was under 1%. As additional validation, we computed overlap between our predictions and a set of ancestral repeats (L2) annotated by RepeatMasker. We found the overlap to be in line with what we expected given our estimated false positive rates: about 5% of the repeats overlap a predicted CE, with around 1.6% nucleotide-level overlap.
Gene, noncoding RNA, and PhastCons conserved element annotations were obtained from the UCSC genome browser's [20] (link), [21] (link) Known Genes [22] (link), RNA Genes, and Conservation [4] (link) tracks respectively. To avoid skewed statistics due to alternative splicing, gene annotations were resolved to a consistent nonoverlapping set where any segment belonging to multiple conflicting annotations was assigned a single annotation in the following order of priority: coding exon, 5′ UTR, 3′ UTR, intron. For meaningful comparison against phastCons, separate GERP++ scores and constrained elements were generated according to the same procedure as above but using only placental mammal data (ignoring platypus and opossum in the alignment and projecting them out of the phylogenetic tree).
PolII binding regions were defined as 50 bp upstream and downstream of PolII binding ‘peaks’ as identified from ChIP-seq experiments performed by the ENCODE Consortium [3] (link). A 100 bp window allows capture of the likely PolII binding site and its flanking sequence. We obtained data from nine ChIP-seq experiments conducted in two labs (the Snyder lab at Yale and the Myers lab at Hudson Alpha) on six cell types. Data was downloaded through the DCC at UCSC (ftp://encodeftp.cse.ucsc.edu). All data have passed publication embargo periods. Overlap statistics were calculated as described above for other annotation sets and averaged across all nine experiments.
Full text: Click here
Publication 2010
3' Untranslated Regions 5' Untranslated Regions Binding Sites Biological Evolution Cells Chromatin Immunoprecipitation Sequencing Chromosomes Didelphidae Eutheria Exons Gene Annotation Genes Genome Genome, Human Homo sapiens Introns Mammals Memory Nucleotides Platypus, Duckbilled RNA, Untranslated Trees Vertebrates X Chromosome Y Chromosome
The numbered positions of annotated residues in the Swiss-Prot sequence often do not align to the same numbered positions of the sequence from the PDB structure. Therefore, a mapping of positions between the Swiss-Prot sequence and the PDB sequence must be obtained. We use a variation of the Needleman and Wunsch algorithm to identify if a sequence of a PDB structure can be found to match the sequence containing annotated residues from the Swiss-Prot database.
Specifically, every Swiss-Prot sequence containing one or more annotated residues and a link to a PDB structure was aligned to the corresponding sequence of the PDB structure. Standard annotations of Swiss-Prot used include post-translational modifications (MOD_RES), covalent binding of a lipid moiety (LIPID), glycosylation sites (CARBOHYD), post-translational formed amino acid bonds (CROSSLNK), metal binding sites (METAL), chemical group binding sites (BINDING), calcium binding regions (CA_BIND), DNA binding regions (DNA_BIND), nucleotide phosphate binding regions (NP_BIND), zinc finger regions (ZN_FING), enzyme activity amino acids (ACT_SITE) and any interesting single amino acid site (SITE). To ensure that the mapping is accurate, only alignments of two sequences with a sequence identity greater than ninety five percent were used. The annotated positions from Swiss-Prot are then transferred onto the PDB sequence, as long as the position is not aligned to a gap.
Publication 2006
Amino Acids Binding Sites Calcium enzyme activity Lipid A Lipids Metals Nucleotides Phosphates Protein Biosynthesis Protein Glycosylation Sequence Alignment Zinc Fingers

Most recents protocols related to «Binding Sites»

Not available on PMC !

EXAMPLE 48

In order to determine B7-1 competition efficiency of CTLA4 binding Nanobodies, the purified clones were tested in an ELISA competition assay setup.

In short, 2 μg/ml B7-1-muFc (Ancell, Bayport, MN, US, Cat #510-820) was immobilized on maxisorp microtiter plates (Nunc, Wiesbaden, Germany) and free binding sites were blocked using 4% Marvel in PBS. Next, 0.33 nM CTLA4-hFc was mixed with a dilution series of purified Nanobody. An irrelevant Nanobody (1A1) was used as a negative controle, since this Nanobody does not bind to CTLA4. As a positive controle for competition with B7-1, the commercial CTLA-4 binding antibody (BNI-3; competing for B7-1 and B7-2) was used. After incubation and a wash step, the CTLA4-hFc was detected with a HRP-conjugated anti-human Fc (Jackson Immunoresearch Laboratories, West Grove, PA, US, Cat #109-116-170) 1:1500 in 2% MPBST. OD values obtained, depicted in FIGS. 26 and 27, show that 2 Nanobodies selected show competition with B7-1 for binding to CTLA4 in a dose-dependent manner.

Full text: Click here
Patent 2024
Binding Sites Biological Assay Clone Cells CTLA4 protein, human Enzyme-Linked Immunosorbent Assay Figs Homo sapiens Immunoglobulins Psychological Inhibition Technique, Dilution Test Preparation VHH Immunoglobulin Fragments
Not available on PMC !

EXAMPLE 49

In order to determine B7-2 competition efficiency of CTLA4 binding Nanobodies, the purified clones were tested in an ELISA competition assay setup.

In short, 5 μg/ml B7-muFc (Ancell, Bayport, MN, Cat #509-820) was immobilized on maxisorp microtiter plates (Nunc, Wiesbaden, Germany) and free binding sites were blocked using 4% Marvel in PBS. Next, 22 nM CTLA4-hFc was mixed with a dilution series of purified Nanobody. An irrelevant Nanobody (1A1) was used as a negative controle, since this Nanobody does not bind to CTLA4. As a positive controle for competition, the commercial CTLA-4 binding antibody (BNI-3; competing for B7-1 and B7-2) was used. After incubation and a wash step the CTLA4-hFc was detected with a HRP-conjugated anti-human Fc (Jackson Immunoresearch Laboratories, West Grove, PA, US, Cat #109-116-170) 1:1500 in 2% MPBST. OD values obtained, depicted in FIGS. 28 and 29, show that 4 Nanobodies selected show competition with B7-2 for binding to CTLA4 in a dose-dependent manner.

Full text: Click here
Patent 2024
Binding Sites Biological Assay Clone Cells CTLA4 protein, human Enzyme-Linked Immunosorbent Assay Figs Homo sapiens Immunoglobulins Psychological Inhibition Technique, Dilution Test Preparation VHH Immunoglobulin Fragments

EXAMPLE 40

In order to determine B7-1 competition efficiency of CD28 binding Nanobodies, the purified Nanobodies that showed binding in the previous binding assay were tested in an ELISA competition assay setup.

In short, 1 μg/ml B7-1-muFc (Ancell, Bayport, MN, US, Cat #510-820) was immobilized on maxisorp microtiter plates (Nunc, Wiesbaden, Germany) and free binding sites were blocked using 4% Marvel in PBS. Next, 2 μg/ml CD28-hFc was mixed with a dilution series of purified Nanobody. An irrelevant Nanobody against FcgR1 (49E4) was used as a negative controle, since this Nanobody does not bind to CD28. After incubation and a wash step the CD28-hFc was detected with a HRP-conjugated anti-human Fc (Jackson Immunoresearch Laboratories, West Grove, PA, US, Cat #109-116-170) 1:1500 in 2% MPBST. The results are shown in FIG. 22. All Nanobodies selected showed competition with B7-1 for binding to CD28 in a dose-dependent manner.

Full text: Click here
Patent 2024
Binding Sites Biological Assay Enzyme-Linked Immunosorbent Assay Homo sapiens Technique, Dilution Test Preparation Titrimetry VHH Immunoglobulin Fragments
Not available on PMC !

EXAMPLE 21

In order to determine PD-1 competition efficiency of B7-H1 binding Nanobodies, the positive clones of the binding assay were tested in an ELISA competition assay setup.

In short, 2 μg/ml B7-H1 ectodomain (rhB7H1-Fc, R&D Systems, Minneapolis, US, Cat #156-B7) was immobilized on maxisorp microtiter plates (Nunc, Wiesbaden, Germany) and free binding sites were blocked using 4% Marvel in PBS. Next, 0.5 μg/ml of PD-1-biotin was preincubated with 10 μl of periplasmic extract containing Nanobody of the different clones and a control with only PD-1-biotin (high control). The PD-1-biotin was allowed to bind to the immobilized ligand with or without Nanobody. After incubation and a wash step, PD-1 binding was revealed using a HRP-conjugated streptavidine. Binding specificity was determined based on OD values compared to controls having received no Nanobody (high control). OD values for the different Nanobody clones are depicted in FIG. 12.

Full text: Click here
Patent 2024
Binding Sites Biological Assay Biotin biotin 1 CD274 protein, human Clone Cells Enzyme-Linked Immunosorbent Assay Ligands Periplasm Psychological Inhibition Test Preparation VHH Immunoglobulin Fragments
Not available on PMC !

EXAMPLE 16

In order to determine competition efficiency of PD-1 binding Nanobodies, the positive clones of the previous binding assay were tested in an ELISA competition assay setup.

In short, 2 μg/ml PD-1 ectodomain (R&D Systems Cat #1086-PD, Minneapolis, US) was immobilized on maxisorp microtiter plates (Nunc, Wiesbaden, Germany) and free binding sites were blocked using 4% Marvel in PBS. Next, 0.5 μg/ml of biotinylated PD-L2 or B7-H1 was preincubated with a dilution series of purified Nanobody. An irrelevant Nanobody against FcgR1 (49C5) was used as a negative controle, since this Nanobody does not bind to PD-1. PD-L2 or B7-H1 without biotin (cold PD-L2 or cold B7-H1) was used as a positive controle for competition. The results are shown in FIGS. 9 and 10. 4 Nanobody families show competition with PD-L2-biotin for binding to PD-1 in a dose-dependent matter. The same 4 Nanobody families also show competition with B7-H1-biotin for binding to PD-1 in a dose-dependent manner.

Full text: Click here
Patent 2024
Binding Sites Biological Assay Biotin CD274 protein, human Clone Cells Cold Temperature Enzyme-Linked Immunosorbent Assay Figs Technique, Dilution Test Preparation Titrimetry VHH Immunoglobulin Fragments

Top products related to «Binding Sites»

Sourced in United States, China, Germany, United Kingdom, Switzerland, Japan, France, Italy, Spain, Austria, Australia, Hong Kong, Finland
The Dual-Luciferase Reporter Assay System is a laboratory tool designed to measure and compare the activity of two different luciferase reporter genes simultaneously. The system provides a quantitative method for analyzing gene expression and regulation in transfected or transduced cells.
Sourced in United States, China, Germany, United Kingdom, Canada, Japan, France, Italy, Switzerland, Australia, Spain, Belgium, Denmark, Singapore, India, Netherlands, Sweden, New Zealand, Portugal, Poland, Lithuania, Hong Kong, Argentina, Ireland, Austria, Israel, Czechia, Cameroon, Taiwan, Province of China, Morocco
Lipofectamine 2000 is a cationic lipid-based transfection reagent designed for efficient and reliable delivery of nucleic acids, such as plasmid DNA and small interfering RNA (siRNA), into a wide range of eukaryotic cell types. It facilitates the formation of complexes between the nucleic acid and the lipid components, which can then be introduced into cells to enable gene expression or gene silencing studies.
Sourced in United States, China, Germany, Japan, United Kingdom, France, Canada, Italy, Australia, Switzerland, Denmark, Spain, Singapore, Belgium, Lithuania, Israel, Sweden, Austria, Moldova, Republic of, Greece, Azerbaijan, Finland
Lipofectamine 3000 is a transfection reagent used for the efficient delivery of nucleic acids, such as plasmid DNA, siRNA, and mRNA, into a variety of mammalian cell types. It facilitates the entry of these molecules into the cells, enabling their expression or silencing.
Sourced in United States, China, Germany, United Kingdom, Switzerland, Finland, Italy, Japan
The Dual-Luciferase Reporter Assay Kit is a laboratory tool that allows for the measurement and quantification of two different reporter luciferase enzymes in a single sample. The kit provides the necessary reagents to perform this dual-reporter analysis, which can be used to study gene expression and regulatory elements.
Sourced in United States, China, France, Japan, United Kingdom
The PmirGLO vector is a dual-luciferase reporter vector used for gene expression analysis. It contains the firefly and Renilla luciferase genes, allowing for simultaneous measurement of both reporter activities in the same sample.
Sourced in United States, China, United Kingdom, Germany, Singapore, Japan
The PsiCHECK-2 vector is a dual-luciferase reporter system used for the analysis of gene expression and regulation. It contains both a firefly luciferase gene and a Renilla luciferase gene, which can be used as an internal control to normalize experimental results.
Sourced in United States, Germany, China, Switzerland, United Kingdom, Japan, Italy, Singapore
The Dual-Glo Luciferase Assay System is a reagent-based detection kit designed to quantify firefly and Renilla luciferase reporter gene activities in a single sample. The system provides a simple, sensitive, and reliable method for cell-based reporter gene analysis.
Sourced in United States, Germany, China, United Kingdom, Japan, Switzerland
The Dual Luciferase Assay System is a laboratory tool designed to quantitatively measure the activity of two different luciferase reporter enzymes within the same sample. It provides a rapid and sensitive method for studying gene expression and regulation in a variety of experimental systems.
Sourced in United States, Germany, China, United Kingdom, Japan, France
The Dual Luciferase Assay Kit is a laboratory tool that measures the activities of two different luciferase reporter enzymes simultaneously within the same sample. The kit provides reagents and protocols to quantify the activities of firefly and Renilla luciferase reporters, allowing for normalization of experimental data.
Sourced in United States, China, Germany, Japan, United Kingdom, France
The PGL3-basic vector is a plasmid designed for routine cloning and reporter gene expression experiments. It provides a basic backbone for inserting genes of interest and evaluating their expression in various cell lines. The vector contains a multiple cloning site for gene insertion and a luciferase reporter gene for downstream analysis.

More about "Binding Sites"

Binding sites are specialized regions on molecules that facilitate critical biological interactions.
These molecular 'docking points' enable the binding of ligands, enzymes, and other biomolecules, playing a crucial role in diverse cellular pathways.
Understanding the structure and function of binding sites is essential for drug discovery, protein engineering, and unraveling complex biological mechanisms.
Leveraging the power of AI-driven research optimization, tools like PubCompare.ai can help scientists locate relevant protocols, preprints, and patents related to binding site analysis.
By seamlessly comparing the best products and methodologies, such as the Dual-Luciferase Reporter Assay System, Lipofectamine 2000, Lipofectamine 3000, Dual-luciferase reporter assay kit, PmirGLO vector, PsiCHECK-2 vector, Dual-Glo Luciferase Assay System, Dual Luciferase Assay System, and Dual luciferase assay kit, researchers can unlock the mysteries of these essential molecular interaction points and accelerate their binding site studies.
Explore the possibilities of AI-assisted binding site research and discover new insights into the complex world of molecular interactions.
Unlock the power of these specialized regions and drive forward groundbreaking discoveries in the fields of drug development, protein engineering, and cellular signaling pathways.